Bedaquiline: what might the future hold?

Journal

The Lancet. Microbe
ISSN: 2666-5247
Titre abrégé: Lancet Microbe
Pays: England
ID NLM: 101769019

Informations de publication

Date de publication:
26 Jul 2024
Historique:
received: 19 01 2024
revised: 27 05 2024
accepted: 29 05 2024
medline: 30 7 2024
pubmed: 30 7 2024
entrez: 29 7 2024
Statut: aheadofprint

Résumé

Tuberculosis drug development has stagnated for decades, so the recent availability of bedaquiline is welcome. Bedaquiline-containing regimens, now the first-line therapy recommended by WHO, have transformed the treatment of drug-resistant tuberculosis, offering safer and more effective oral treatment options. However, key obstacles need to be overcome to ensure global access and prevent the rapid development of resistance against this promising class of drugs. In this Personal View, building on an international workshop held in 2023, we evaluate the current evidence and suggest possible ways forward, recognising the tension between increasing use and slowing the rise of resistance. We also discuss problems in accessing bedaquiline-containing regimens, the potential widening of their use beyond drug-resistant tuberculosis, and lessons for utilising new drugs as they are developed.

Identifiants

DOI: 10.1016/S2666-5247(24)00149-6 PMID: 39074472
pubmed: 39074472
pii: S2666-5247(24)00149-6
doi: 10.1016/S2666-5247(24)00149-6
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

100909

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declarations of interests CL is supported by the German Center of Infection Research (DZIF) under agreement TTU-TB 02.709. Beyond the scope of this Personal View, he receives consulting fees from INSMED and Janssen; honoraria from INSMED, Gilead Sciences, AstraZeneca, GSK, medUpdate, medUpdateEurope, and the Konrad-Adenauer-Foundation; and is a member of the Data Safety Board of trials from Médecins Sans Frontières. JLP is paid for advisory work for TMLEP. In an unpaid capacity, JLP is co-chair of UK Academics and Professionals to End TB, is a member of the Innovations Constituency Stop TB Partnership, and owns TB Drug Monographs. LL has received funding from Gilead Sciences Inc and support for travel from Roche.

Auteurs

Emily S Shaw (ES)

Division of Acute Medical Services, University College London Hospitals NHS Foundation Trust, London, UK. Electronic address: emily.shaw25@nhs.net.

Neil G Stoker (NG)

Centre for Clinical Microbiology, Royal Free Campus, University College London, London, UK.

Jessica L Potter (JL)

Respiratory Medicine, Division of Medicine, University College London, London, UK; Department of Respiratory Medicine, North Middlesex University Hospital, London, UK.

Helgard Claassen (H)

Africa Health Research Institute, Durban, South Africa.

Alasdair Leslie (A)

Department of Infection and Immunity, University College London, London, UK; Africa Health Research Institute, Durban, South Africa.

Conor D Tweed (CD)

MRC Clinical Trials Unit, University College London, London, UK.

Chen-Yuan Chiang (CY)

Division of Pulmonary Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; International Union Against Tuberculosis and Lung Disease, Paris, France.

Francesca Conradie (F)

Clinical HIV Research Unit, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Hanif Esmail (H)

MRC Clinical Trials Unit, University College London, London, UK; Institute for Global Health, University College London, London, UK; Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Christoph Lange (C)

Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany; German Center of Infection Research (DZIF), Borstel, Germany; Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.

Lancelot Pinto (L)

PD Hinduja National Hospital and Medical Research Centre, Mumbai, India.

Oxana Rucsineanu (O)

Moldova National Association of Tuberculosis Patients (SMIT), Bălți, Republic of Moldova.

Derek J Sloan (DJ)

School of Medicine, University of St Andrews, St Andrews, UK.

Grant Theron (G)

Department of Science and Innovation-National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Phumeza Tisile (P)

NGO TB Proof, Cape Town, South Africa.

Teck Chuan Voo (TC)

Office of Ethics in Healthcare, SingHealth, Singapore.

Robin M Warren (RM)

Department of Science and Innovation - National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Cape Town, South Africa; South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Limakatso Lebina (L)

Africa Health Research Institute, Durban, South Africa.

Marc Lipman (M)

Respiratory Medicine, Division of Medicine, University College London, London, UK; Royal Free London NHS Foundation Trust, London, UK.

Classifications MeSH